Document is current
Any future updates will be listed below
-
Authors
Herrick, Ariane L. https://orcid.org/0000-0003-4941-7926
Assassi, Shervin https://orcid.org/0000-0002-8059-9978
Denton, Christopher P. https://orcid.org/0000-0003-3975-8938
- License Information
-
More Information
Article History
Accepted: 16 February 2022
First Online: 15 March 2022
Competing interests
: A.H. has received consultancy fees from Boehringer-Ingelheim, Camurus, CSL Behring and Gesynta, research funding from Gesynta and speaker’s fees from Janssen. S.A. has received grant support from Boehringer-Ingelheim, Janssen and Momenta Pharmaceuticals, and has received personal fees for participation in advisory board meetings from AstraZeneca, Boehringer-Ingelheim, Corbus Pharmaceuticals, CSL Behring and Novartis. C.D. has received grants and personal fees from CSL Behring and GlaxoSmithKline, grants from Arxx Therapeutics, Inventiva and Servier, and personal fees from Acceleron, Bayer, Boehringer-Ingelheim, BristolMyersSquibb, Corbus, Horizon, Roche and Sanofi.
